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SUMMARY
The process of prescribing changes as children move into adulthood. For some medicines, such as 
psychotropic drugs, safety and efficacy are less well understood in adolescents.
As adolescents mature they attain the capacity to consent to their own medical treatment. 
An assessment of their competency will need to take into account the nature of the treatment 
being proposed.
Parental involvement is usually beneficial particularly for adolescents with chronic or complex 
conditions, but increasing adolescent autonomy needs to be respected.
Adherence to treatment can be supported by understanding adolescent development and 
involving adolescents in management plans.
Prescribing for adolescents
functions are to adults. This makes pharmacokinetic 
considerations simpler than they are in children.3 
Nevertheless, physiological phenomena such as 
growth plate fusion and bone mass accrual which 
occur during puberty have implications for some 
prescribing decisions. For example, long-term use 
of depo-medroxyprogesterone is associated with 
osteoporosis, and long-term oral corticosteroids have 
the potential to affect growth. It is also important 
for clinicians who may have been prescribing drugs 
such as antiepileptics for adolescents when they 
were children to consider their sexual maturation 
and the possibility of pregnancy. Issues such 
as sexuality should be raised in a sensitive and 
confidential manner.
In younger adolescents whose peak growth velocity 
is still underway, paediatric dose calculations may 
be needed for some drugs, especially those with 
significant adverse effects. While several classes of 
drugs are safe to use in adult doses for adolescents 
aged 12 years and over, many have not been studied 
in this population, including psychotropic drugs.4 
Clinicians often prescribe medicines off label with 
decisions based on research from adults because of 
limited knowledge about dosing, efficacy and safety 
in adolescents.5
For antidepressants, current evidence shows a 
modest benefit for only one drug in this age group 
(fluoxetine).6 There are also concerns about the risk 
of harm. Mild to moderate depression should be 
treated with non-pharmacological therapy. Decision 
making regarding psychotropic drugs requires careful 
consideration. A thorough assessment of mental 
health symptoms, a comprehensive biopsychosocial 
assessment,7 and a risk and safety assessment are 
warranted. Drug therapy is more likely to be indicated 
Introduction
The challenges in prescribing for adolescents fall into 
four main categories:
 • medicine safety and efficacy, taking into account 
the physiology of puberty
 • the increasing autonomy of the adolescent patient
 • conscious or unconscious clinician bias regarding 
young people
 • concerns about adherence.
Prescribing decisions will involve clinical judgement, 
the adolescent’s preferences, parent’s or carer’s 
wishes and the medicolegal framework.
Prescribing patterns for 
adolescent patients
Adolescents are defined by the World Health 
Organization as those aged 10–19 years. There are 
very little up-to-date data on prescription rates 
specifically for the adolescent population. An analysis 
of general practice surveillance data from 1998 to 
2005 found the most frequently prescribed drugs 
in this age group were antibiotics for respiratory 
infections, antidepressants for anxiety or depression, 
and bronchodilators and corticosteroids for asthma.1 
Among 14–17-year-old females, contraception is the 
second most commonly managed problem. Less than 
two-thirds of contraceptive prescriptions in this age 
group are for contraception, with menstrual problems 
and acne accounting for the rest.2
Safety and efficacy
It is important not to view adolescents as ‘mini adults’ 
when it comes to prescribing, although in general, 
the more advanced an adolescent is in puberty, 
the more similar their body composition and organ 
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in moderate to severe depression or anxiety, in 
conjunction with non-pharmacological therapy,6 and 
is a shared process with the adolescent (and parent 
or caregiver). Collaboration with others involved in 
care, such as a psychologist and school counsellor, 
is important, as well as considering the need for a 
psychiatric opinion.
Capacity to consent to 
medical treatment
Adolescents attain cognitive capacity for reasoning 
and abstract thinking that, under Australian law, can 
afford them the legal status of ‘mature minor’. All 
jurisdictions in Australia allow for the Common Law 
test of ‘Gillick competence’ which recognises that an 
adolescent under the age of 18 may have the capacity 
to consent to medical treatment on their own behalf 
and without their parents’ knowledge.8 Additional 
legislation in South Australia and New South Wales 
grants adolescents aged 16 years and over (rather 
than 18 years) the right to consent to their own 
treatment as adults.9
An assessment of the adolescent’s competency needs 
to be assessed in each case on a continual basis, and 
should consider the maturity of the adolescent as well 
as the nature and the complexity of the treatment. 
To be competent the adolescent should be able 
to understand:7
 • what the treatment is for and why it is necessary
 • any treatment options or alternatives
 • what the treatment involves
 • likely effects and possible adverse effects
 • seriousness of the treatment
 • consequences of not treating.
Options including the benefits and harms of 
treatment versus those of non-drug treatment 
should be discussed. Asking the adolescent to 
explain their own understanding of this can be 
helpful. It should be noted however that adults 
also have misunderstandings about medicines – 
this is not unique to adolescents. For example, a 
large household survey in the UK found substantial 
misinformation about antibiotics.10 If unsure of an 
adolescent’s capacity to consent, it is important to 
seek advice from a clinician with expertise in this area. 
In very complex cases a medical defence organisation 
may be able to provide advice.
Confidentiality
If adolescents ask for their parents not to be 
informed about their prescription, it is important 
to enquire about this wish. The concept of safety 
is understood by adolescents and is the basis for 
explaining exceptions to confidentiality. Discussing 
the adolescent’s safety regarding drug treatment, 
as well as their health problem as the initial and 
primary concern, can be a useful way to encourage 
more openness with the parents. It can be revealing 
as well as practical to discuss with an adolescent 
what would happen if a family member were to 
discover their medicines. This can be a ‘reality check’ 
as well as an opportunity to anticipate reactions. 
Importantly, even though an adolescent may not want 
to involve a parent initially, this can change and it is 
important to maintain an ongoing dialogue about this. 
It is essential also that the adolescent understands 
confidentiality and its limits, and that if there are 
concerns about safety with risk to themselves, or 
others, there would be a need to inform their parent 
or caregiver.
If there are circumstances where an adolescent 
decides not to inform their parents, the context 
behind this should be explored and the reasons 
documented by the prescriber, as well as 
documenting having offered to speak with a parent.
The shifting power dynamics in the adolescent–
parent–clinician triad is a challenge for many 
clinicians. Difficulties reported by GPs include, 
on the one hand, negotiating time alone with 
adolescents to facilitate engagement, while on 
the other hand, feeling that adolescents are not 
sufficiently responsible to manage their health 
alone.11 What is unknown is whether clinicians 
change their prescribing behaviour as a result of 
these difficulties. For example, there is no published 
research that has explored prescribing decisions on 
the basis of parental presence or absence during 
consultations, whether parental consent is sought 
when prescribing for minors, and how often and for 
which drugs, or whether competency assessments 
are made.
Possible bias
There is also a dearth of information about the 
influence of conscious or unconscious bias towards 
young people in prescribing decisions, although 
interesting evidence is emerging in the area of 
contraception. A study among young Australian 
women (18–23 years) found that they perceived 
that doctors provided incomplete information 
about, and limited their options for, contraception 
because they were young.12 A recent qualitative 
study involving young women (16–24 years) of 
culturally diverse backgrounds also suggested 
that clinicians may be selective about the 
contraception options they offer.13 The uptake of 
long-acting reversible contraceptives has been 
slow among Australian women, despite them being 
recommended as first-line options for nulliparous 
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Prescribing for adolescents
women in Australia, the USA and the UK.14 This may 
be because Australian women and clinicians are 
unfamiliar with long-acting reversible contraceptives, 
compared to the combined oral contraceptive 
pill.14 However, there is a need to understand 
whether clinicians are consciously ‘gatekeeping’ 
and if so what influences this. Young women have 
the right to be informed about the full range of 
contraception options.
Adherence
Adherence to treatment is another challenge when 
prescribing for adolescents, particularly for those 
with a chronic illness such as diabetes. Rather than 
make assumptions about non-adherence among 
adolescents, it is the role of clinicians to work with 
adolescents to optimise adherence just as they 
would with adults. Understanding adolescent brain 
development, and how this influences behaviour, risk-
taking and decision making, can inform approaches to 
self-management.
In adolescence, peers have an impact on the 
processing of social information, resulting in a 
heightened sensitivity to peer attitudes. Adolescents 
are also more likely than adults to seek out situations 
that are arousing, exciting or stressful and they 
have greater difficulty than adults in overriding 
‘high emotions’.15
Understanding neurodevelopmental phenomena can 
help clinicians as well as the designers of programs 
intended to support adolescents with chronic illness 
as they transition from paediatric to adult care. 
Shared decision making is a goal in the management 
of chronic health conditions and enhances adherence, 
as do strategies such as motivational interviewing 
and pharmacist support.16 As children move into 
adolescence, the process of shared decision making 
needs to be supported by clinicians in consultation 
with the patient and their parents or carers. Listening 
to the adolescent’s concerns can identify previously 
unconsidered barriers that may be amenable to 
change, such as dosage regimens interfering with 
school timetables, or concerns about adverse effects 
based on (mis)information on the internet or among 
peers. After identifying these concerns, additional 
strategies may include:
 • education – providing accurate information 
and repeating at regular intervals in a variety of 
formats, for example verbal, written information, 
websites, books
 • organisational – simple dosing, once-daily, 
extended-release formulations, alarms on 
watches, reminders on phones
 • behavioural and problem solving, for example 
pairing taking medicines with other well-
established behaviours
 • peer and family support
 • motivational interviewing techniques.
Evaluation of adherence is important at regular 
intervals when the adolescent and family have 
an opportunity to ask questions and discuss any 
treatment-related concerns.17
Conclusion
Adolescents are a group who are in a dynamic 
process of acquiring autonomy in all areas of 
life, including health care and self-management. 
Clinicians play a vital role in supporting this process 
and engaging adolescents in a provider–patient 
relationship that can have a positive impact on 
their health. Challenges around medicine safety, 
medicolegal concerns, clinician awareness about 
treatment bias, navigating the shifting dynamics 
in the parent–patient–clinician relationship, and 
finding strategies for improving adherence and 
self-management can all be addressed by first 
understanding adolescent development. Assessing 
psychosocial as well as medical histories should be 
routine and helps to build an empathic and trusting 
relationship with adolescent patients. 
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